StockData
NovoCure Ltd logo

NovoCure Ltd (NVCR) stock

NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3031% below fair value
$11.14−0.16 (-1.42%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

NovoCure total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

NovoCure's total debt was $25.00M at Sep 30, 2026. For fiscal 2025 it was $195.05M, up 100.5% from the year before. Over ten years it grew 23.7% a year on average. The highest annual figure on record is $568.82M in fiscal 2023.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$195.05M+100.5%
FY2024Dec 31, 2024$97.30M-82.9%
FY2023Dec 31, 2023$568.82M+0.6%
FY2022Dec 31, 2022$565.51M+0.6%
FY2021Dec 31, 2021$562.22M+30.8%
FY2020Dec 31, 2020$429.91M+187.7%
FY2019Dec 31, 2019$149.42M+0.1%
FY2018Dec 31, 2018$149.30M+53.3%
FY2017Dec 31, 2017$97.37M+1.1%
FY2016Dec 31, 2016$96.30M+315.8%
FY2015Dec 31, 2015$23.16M–
FY2014Dec 31, 2014$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$25.00M-95.6%
Q4 FY2025Dec 31, 2025$195.05M-65.7%
Q4 FY2024Dec 31, 2024$97.30M-82.8%
Q1 FY2024Mar 31, 2024$569.65M+0.6%
Q4 FY2023Dec 31, 2023$568.82M+0.6%
Q3 FY2023Sep 30, 2023$567.99M+0.6%
Q2 FY2023Jun 30, 2023$567.15M+0.6%
Q1 FY2023Mar 31, 2023$566.32M+0.6%
Q4 FY2022Dec 31, 2022$565.51M+0.6%
Q3 FY2022Sep 30, 2022$564.68M+0.6%
Q2 FY2022Jun 30, 2022$563.85M+0.6%
Q1 FY2022Mar 31, 2022$563.03M+0.6%
Q4 FY2021Dec 31, 2021$562.22M+30.8%
Q3 FY2021Sep 30, 2021$561.39M–
Q2 FY2021Jun 30, 2021$560.56M+274.9%
Q1 FY2021Mar 31, 2021$559.58M+274.4%
Q4 FY2020Dec 31, 2020$429.91M+187.7%
Q3 FY2020Sep 30, 2020$0-100.0%
Q2 FY2020Jun 30, 2020$149.51M+0.1%
Q1 FY2020Mar 31, 2020$149.47M+0.1%
Q4 FY2019Dec 31, 2019$149.42M+0.1%
Q3 FY2019Sep 30, 2019$149.38M+0.1%
Q2 FY2019Jun 30, 2019$149.34M+0.1%
Q1 FY2019Mar 31, 2019$149.31M+0.1%
Q4 FY2018Dec 31, 2018$149.30M+53.3%
Q3 FY2018Sep 30, 2018$149.23M+53.8%
Q2 FY2018Jun 30, 2018$149.20M+54.2%
Q1 FY2018Mar 31, 2018$149.16M+54.6%
Q4 FY2017Dec 31, 2017$97.37M+1.1%
Q3 FY2017Sep 30, 2017$97.05M–
Q2 FY2017Jun 30, 2017$96.77M–
Q1 FY2017Mar 31, 2017$96.49M–
Q4 FY2016Dec 31, 2016$96.30M–

More NovoCure figures

See a number that looks wrong?